Literature DB >> 28325637

Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.

Mark C Markowski1, Philip Imus2, Jean L Wright3, Douglas Schottenstein4, Channing J Paller2.   

Abstract

Entities:  

Keywords:  PSA; Radiation; SBRT

Mesh：

Substances：

Year:  2017        PMID： 28325637      PMCID： PMC5801746          DOI： 10.1016/j.clgc.2017.02.001

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  12 in total

1.  Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer.

Authors:  M I Martínez-Fernández; J L Pérez Gracia; I Gil-Bazo; R Martínez-Monge
Journal:  Clin Transl Oncol       Date:  2015-10-19       Impact factor: 3.405

2.  Diagnostic challenges of clonal heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Angelo M De Marzo; Srinivasan Yegnasubramanian; Jonathan I Epstein; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

Review 4.  Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective.

Authors:  Muhammed Ahmed; Long-Cheng Li
Journal:  Int J Urol       Date:  2012-11-19       Impact factor: 3.369

5.  Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

Authors:  Sean O'Farrell; Hans Garmo; Lars Holmberg; Jan Adolfsson; Pär Stattin; Mieke Van Hemelrijck
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544

6.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

Authors:  Piet Ost; Barbara Alicja Jereczek-Fossa; Nicholas Van As; Thomas Zilli; Alexander Muacevic; Kenneth Olivier; Daniel Henderson; Franco Casamassima; Roberto Orecchia; Alessia Surgo; Lindsay Brown; Alison Tree; Raymond Miralbell; Gert De Meerleer
Journal:  Eur Urol       Date:  2015-07-16       Impact factor: 20.096

7.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.

Authors:  Michael T Milano; Alan W Katz; Hong Zhang; Paul Okunieff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-13       Impact factor: 7.038

8.  Is there a favorable subset of patients with prostate cancer who develop oligometastases?

Authors:  Deepinder Singh; Won Sam Yi; Ralph A Brasacchio; Ann G Muhs; Therese Smudzin; Jacqueline P Williams; Edward Messing; Paul Okunieff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038

Review 9.  Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.

Authors:  Onita Bhattasali; Leonard N Chen; Michael Tong; Siyuan Lei; Brian T Collins; Pranay Krishnan; Christopher Kalhorn; John H Lynch; Simeng Suy; Anatoly Dritschilo; Nancy A Dawson; Sean P Collins
Journal:  Front Oncol       Date:  2013-12-03       Impact factor: 6.244

10.  SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.

Authors:  Gregory Azzam; Rachelle Lanciano; Steve Arrigo; John Lamond; William Ding; Jun Yang; Alexandra Hanlon; Michael Good; Luther Brady
Journal:  Front Oncol       Date:  2015-05-05       Impact factor: 6.244
View more
  4 in total

Review 1.  Oligometastatic prostate cancer: Reality or figment of imagination?

Authors:  Corey C Foster; Ralph R Weichselbaum; Sean P Pitroda
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

Review 2.  Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer.

Authors:  Matthew P Deek; Ryan M Phillips; Phuoc T Tran
Journal:  Semin Radiat Oncol       Date:  2021-07       Impact factor: 5.421

Review 3.  Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer.

Authors:  Matthew P Deek; Phuoc T Tran
Journal:  Cancer J       Date:  2020 Mar/Apr       Impact factor: 2.074

4.  A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).

Authors:  Hamza Hasan; Matthew P Deek; Ryan Phillips; Robert F Hobbs; Reem Malek; Noura Radwan; Ana P Kiess; Shirl Dipasquale; James Huang; Terry Caldwell; Jessica Leitzel; Danielle Wendler; Hao Wang; Elizabeth Thompson; Jonathan Powell; Sara Dudley; Curtiland Deville; Stephen C Greco; Daniel Y Song; Theodore L DeWeese; Michael A Gorin; Steven P Rowe; Sam Denmeade; Mark Markowski; Emmanuel S Antonarakis; Michael A Carducci; Mario A Eisenberger; Martin G Pomper; Kenneth J Pienta; Channing J Paller; Phuoc T Tran
Journal:  BMC Cancer       Date:  2020-06-01       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.